Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 12 versus FENTANYL CITRATE AND DROPERIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL 12 versus FENTANYL CITRATE AND DROPERIDOL.
FENTANYL-12 vs FENTANYL CITRATE AND DROPERIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a synthetic opioid agonist primarily acting on mu-opioid receptors in the central nervous system, leading to analgesia, sedation, and respiratory depression.
Fentanyl is a mu-opioid receptor agonist, producing analgesia and sedation. Droperidol is a butyrophenone antipsychotic that blocks dopamine D2 receptors in the brain, causing tranquilization and antiemetic effects.
Transdermal: 12 mcg/hour applied every 72 hours. For opioid-tolerant patients only.
Fentanyl 50-100 mcg IV and droperidol 2.5-5 mg IV, administered slowly over 1-2 minutes, repeated every 60 minutes as needed for breakthrough pain or sedation.
None Documented
None Documented
Terminal elimination half-life is 3–12 hours (mean ~7 hours) in adults. Prolonged in elderly, hepatic impairment, and obesity (up to 20 hours). Context: half-life increases with continuous infusion (context-sensitive half-life).
Fentanyl: 3-4 hours (terminal elimination half-life); prolonged in elderly and hepatic impairment. Droperidol: 2.2-2.5 hours (terminal elimination half-life).
Primarily hepatic metabolism (N-dealkylation and hydroxylation) with <10% excreted unchanged in urine. Renal excretion accounts for ~75% of total elimination as metabolites; fecal excretion ~9%.
Fentanyl: primarily renal (75% as metabolites, <10% unchanged), with about 9% excreted in feces. Droperidol: renal (75% as metabolites, <1% unchanged), about 22% in feces.
Category D/X
Category D/X
Opioid Agonist
Opioid Agonist